iiinova — where your digital self keeps evolving

Reposted by Jose Tapia

John McGrane @jmcgrane.bsky.social · 24/06/2025

📢Calling all Renal Clinicians Screening Brain Imaging in asymptomatic metastatic #RenalCancer is an ongoing area of debate UK ROC is trying to get a picture of imaging practice across the UK (&beyond)! Get involved! 4 minute survey below👇 forms.gle/RmsAWug54YxZ... @tapiajc.bsky.social

forms.gle

CNS imaging for renal cell carcinoma

Background: Brain metastases are a critical site of disease progression in patients with metastatic renal cell carcinoma (mRCC). They are associated with a lower median and overall survival rate. A re...

021

Reposted by Jose Tapia

John McGrane @jmcgrane.bsky.social · 29/05/2025

🚨May is Bladder Cancer awareness month🚨 What better way to mark this than a Simply Oncology Bladder Cancer episode with the irrepressible @alisonbirtle.bsky.social 🎙️We discuss peri-operative treatment & NIAGARA trial #BladderCancer @tapiajc.bsky.social @achoud72.bsky.social @abcuk.bsky.social

052

Jose Tapia @tapiajc.bsky.social · 02/05/2025

Powerful message from Prof Rob Jones. A must for all oncologists treating #BladderCancer in the UK, particularly for trainees. Treatment strategies are evolving and we need to remember: “treat the patient, not the service”.

000

Jose Tapia @tapiajc.bsky.social · 27/04/2025

Looking forward to #ASCO25. I tried to summarise it, but there’s some really exciting new data. #Bladder new ADCs strategies, pt selection, ctDNA, non-UC subtypes, RT + IO. #Kidney biomarkers, new TKI & HIFi, nccRCC #Prostate new drugs, pt selection, aggressive variants.

001

Jose Tapia @tapiajc.bsky.social · 09/04/2025

Grateful to be included on this list alongside such great minds as Dr @yukselurun.bsky.social Much appreciated, @Larvol 😊

011

Jose Tapia @tapiajc.bsky.social · 06/04/2025

=>2L at #O3B trial in #RCC #ASCOGU25. Would you try the new anti-CTLA4 (Quavonlimab) in anti-CTLA4-naive pts? PEM/Q vs PEM/Len. ORR: 30% vs 40%. 1yPFS: 39% vs 34%. 1yOS 75% vs 82%. TRAE: 25% vs 49% irAE: 20% vs 44% (only 5% G3+) Treatment every 6 weeks. @rickyfrazer1.bsky.social

000

Reposted by Jose Tapia

John McGrane @jmcgrane.bsky.social · 13/03/2025

🎙️@simplyoncology.bsky.social episode on #BladderCancer out 14/03/2025 🎙️We talk to leading bladder radiotherapy expert Professor Ananya Choudhury. 🎙️@achoud72.bsky.social discusses her views on bladder preservation and radiotherapy. 🎙️Fascinating insights from a world expert in bladder cancer 👇

012

Reposted by Jose Tapia

Nick James @prof-nick-james.bsky.social · 07/01/2025

Latest edition of our Trials and Tribulations now out featuring @gu-cast.bsky.social Declan Murphy on the role of urologists in trial design and conduct. open.spotify.com/episode/2SKX...

open.spotify.com

Episode 12: Involve Your Urologist! Challenges facing surgical trials featuring Professor Declan Murphy

Trials and Tribulations | Oncology Trials Podcast · Episode

042

Reposted by Jose Tapia

John McGrane @jmcgrane.bsky.social · 07/03/2025

Out today on @simplyoncology.bsky.social 🎙️Excellent follow on to last weeks ESMO Resilience Taskforce episode. 🎙️We talk to @susanabanerjee.bsky.social about individual challenges of resilience. 🎙️Susie shares some great insights on this important and common issue #burnout @drjonlim.bsky.social

012

Reposted by Jose Tapia

John McGrane @jmcgrane.bsky.social · 20/02/2025

📣New episode out tomorrow on @simplyoncology.bsky.social podcast 🎙️we discuss the Current and Future Shape of Oncology with @tomroques.bsky.social the vice president of @rcradiologists.bsky.social 🎙️ Be sure to check it out.

064

Jose Tapia @tapiajc.bsky.social · 10/02/2025

Looking forward to #ASCOGU25 #Prostate: Combos w/ iPARP- and Lu- , EZH2 #Urothelial: Updates, HER-2, FGFR3, and high-risk UTUC #Renal: Updates, UO3B, KIM-1, HIF-2 inh and MET inh #Testicular: RPLND advanced Seminoma #Penile: IO-chemo for advanced Ca @rickyfrazer1.bsky.social @jmcgrane.bsky.social

000

Jose Tapia @tapiajc.bsky.social · 03/02/2025

Great podcast, John! I finally understand what PACE A, B, C , and NODE means! 🤣 I was kind of lost in my MDT.

100

Reposted by Jose Tapia

Sabine D. Brookman-May, MD, FEBU🚴‍♀️🚴‍♀️🚴‍♀️🏔️⛷️⛰️ @brookmans76.bsky.social · 11/01/2025

#CREST trial with positive results for #PD-1 in HR #NMIBC! ✅The study evaluated #sasanlimab (PD-1i)+BCG vs standard #BCG (induction + maintenance) in BCG-naïve, HR NMIBC. ✅The study met its primary endpoint with significant improvement of EFS pfizer.com/news/press-rel… @oncodaily.bsky.social

pfizer.com

153

Reposted by Jose Tapia

Richard Simcock @breastdocuk.bsky.social · 20/11/2024

So here’s a starter pack of the UK Oncologists I’ve found so far - LMK who I have missed and I will follow and add.

132711

Reposted by Jose Tapia

John McGrane @jmcgrane.bsky.social · 10/01/2025

🎙️New Simply Oncology episode out today. 🎙️Ep 32: Discussing Global Oncology with Dr Susannah Stanway🌍 🎙️We look at the challenges affecting delivery of cancer care in Low and Middle Income countries. Check it out 👇 www.buzzsprout.com/2342317/epis... #cancer #oncology #cancerequity

022

Reposted by Jose Tapia

Yüksel Ürün @yukselurun.bsky.social · 07/01/2025

Belzutifan + Cabozantinib shows promising 70% ORR in treatment-naive advanced ccRCC (LITESPARK-003). #KidneyCancer #Oncology #Cancer @oncoalert.bsky.social @drchoueiri.bsky.social @kidney-cancer.bsky.social @dfcibreastonc.bsky.social

0104

Reposted by Jose Tapia

John McGrane @jmcgrane.bsky.social · 01/01/2025

🚦First episode of 2025 Simply Oncology podcast out Friday with the ever excellent Alison Birtle🎙️ We covered ‘The Triple Question in mHSPC in the last episode 🎯 🎙️This time we cover all things metastatic castrate resistant prostate cancer🎙️ @alisonbirtle.bsky.social @simplyoncology.bsky.social

022

Reposted by Jose Tapia

Chris Parker @ccparker.bsky.social · 26/12/2024

A must-read for anyone with an interest in NHS whistleblowers. Shocking but highly readable, culminating in a surgeon being struck off, but only after many patients harmed #medsky #prostatecancer #nhs

1124

Jose Tapia @tapiajc.bsky.social · 12/12/2024

Excited to be in Barcelona for the 2nd #GuardConsortium meeting on drug development and regulations for urological cancer. Happy to discuss global disparities in drug approvals for #UrothelialCarcinoma.

000

Reposted by Jose Tapia

Yüksel Ürün @yukselurun.bsky.social · 07/12/2024

NURE-Combo trial: Neoadjuvant nivolumab + nab-paclitaxel achieved a 32.3% pathologic CR (ypT0N0) and 70.9% major pathologic response (ypT≤1N0-x) in MIBC. 12-month EFS: 89.8%. Promising results for cisplatin-ineligible patients! #BladderCancer #Immunotherapy #Oncology @oncoalert.bsky.social

0143

Reposted by Jose Tapia

European Association of Urology (EAU) @uroweb.org · 12/11/2024

For those in urology, this starter pack has all you need to keep things flowing in the Blue Zone! #urology #urologylife go.bsky.app/TSRtV3g

33316